Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
21460076

DOI
10.1177/1741826711406616

Original Paper URL
http://cpr.sagepub.com/content/19/3/474.abstract

Indexing Status
Subject indexing assigned by NLM

MeSH
Atorvastatin Calcium; Bayes Theorem; Cardiovascular Diseases /drug therapy /economics /prevention & control; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Costs; Drug Prescriptions /economics; Drugs, Generic /administration & dosage /economics; Fluorobenzenes /administration & dosage /economics; Heptanoic Acids /administration & dosage /economics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors /administration & dosage /economics; Markov Chains; Medication Adherence; Models, Economic; Pyrimidines /administration & dosage /economics; Pyrroles /administration & dosage /economics; Quality Indicators, Health Care /economics; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention /economics; Simvastatin /administration & dosage /economics; Sulfonamides /administration & dosage /economics; Time Factors; Treatment Outcome

AccessionNumber
22012033951

Date bibliographic record published
06/02/2013